Free shipping on all orders over $ 500

Rilzabrutinib

Cat. No. M10605

All AbMole products are for research use only, cannot be used for human consumption.

Rilzabrutinib Structure
Synonym:

PRN1008

Size Price Availability Quantity
1mg USD 115  USD115 In stock
5mg USD 300  USD300 In stock
10mg USD 480  USD480 In stock
25mg USD 850  USD850 In stock
50mg USD 1200  USD1200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of 1.3 nM. Cysteine targeting of BTK by Rilzabrutinib results in a slow off-rate demonstrated by retention of 79±2% of binding to BTK in PBMC 18 hours after washing away the compound in vitro. The covalent cysteine binding is completely reversible after denaturation of the target. Anti-IgM induces human B cell proliferation (10% serum) and B cell CD69 expression are inhibited by Rilzabrutinib with IC50 of 5±2.4 nM and 123±38 nM, respectively.

Chemical Information
Molecular Weight 665.76
Formula C36H40FN9O3
CAS Number 1575596-29-0
Solubility (25°C) DMSO ≥ 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Rundan Duan, et al. Front Cardiovasc Med. Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

[2] Aikaterini Patsatsi, et al. Front Med (Lausanne). Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

[3] Datong Zhang, et al. Molecules. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

[4] Claire L Langrish, et al. J Immunol. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

[5] Patrick F Smith, et al. Br J Clin Pharmacol. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Related BTK Products
BIIB129

BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells.

UBX-382 

UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling.

GDC-0834 

GDC-0834 is a potent and selective BTK inhibitor.

DD-03-171 

DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM.

N-piperidine Ibrutinib hydrochloride 

N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative.

  Catalog
Abmole Inhibitor Catalog




Keywords: Rilzabrutinib, PRN1008 supplier, BTK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.